NF-E2 related factor 2 (Nrf2) was originally defined as a basic leucine zipper (b-Zip) transcriptional activator that recognizes the nuclear factor erythroid 2 (NF-E2)-binding site (Moi et al., 1994; Itoh et al., 1995) . Nrf2 is essential for the coordinate transcriptional induction of various antioxidant and phase II drug-metabolizing enzymes through the antioxidant response element/ electrophile response element (ARE/EpRE) (Itoh et al., 1997 (Itoh et al., , 1999 . ARE/EpRE sequences have been characterized within the proximal regulatory sequences of genes encoding the antioxidant enzymes glutathione S-transferase (GST) (Rushmore et al., 1990 ), NAD(P)H quinone oxidoreductase (NQO1) (Favreau and Pickett, 1991) , heme oxygenase-1 (HO-1) (Prestera et al., 1995) , g-glutamylcysteine synthetase (Chan and Kwong, 2000) , and cystine membrane transporter (system X c À ) (Ishii et al., 2000) . The ARE also regulates a wide range of metabolic responses to oxidative stress caused by reactive oxygen species (ROS) or electrophiles (Ishii et al., 2000) . As a consequence of inadequate induction of these molecules, Nrf2-deficient mice are sensitive to high oxidative stress and drug-induced stress (Ishii et al., 2000; Enomoto et al., 2001; Cho et al., 2002) .
Glutathione (l-g-glutamyl-cysteinyl-glycine, GSH) is a tripeptide, intracellular, nonprotein thiol that has a central role in sulfhydryl homeostasis. GSH serves as the major cytosolic antioxidant and defends against xenobiotics by acting as a substrate during phase II conjugation reactions (Jones et al., 1986; Meister, 1992) . Numerous cellular functions are modulated by the glutathione disulfide system, including regulation of enzymes vital to metabolism, cell growth, gene transcription, and apoptosis (Uhlig and Wendel, 1992; Droge et al., 1994; Hall, 1999) . Therefore, cells tightly regulate the synthesis, utilization, and export of GSH. The intracellular concentration of GSH is maintained within the millimolar range under normal conditions (Anderson, 1997) . The synthesis of GSH is achieved by the consecutive action of the ATP-dependent enzymes, g-glutamylcysteine synthetase and glutathione synthetase. It was reported that levels of both these key enzymes are affected by the activity of Nrf2 (Chan and Kwong, 2000) . In addition, the expression of system X c À is controlled by Nrf2 (Ishii et al., 2000) . System X c À regulates the concentration of intracellular cystine, a component substrate for GSH synthesis. Based upon these findings, Nrf2 is thought to be one of the main regulators of intracellular GSH levels.
The cytokine receptor Fas (APO-1/CD95) belongs to the tumor necrosis factor (TNF)/nerve growth factor receptor superfamily. Certain members of this family, including Fas, are referred to as death receptors since they share a cytoplasmic death domain involved in apoptotic signaling (Schulze-Osthoff et al., 1998) . Fas is expressed by lymphoid and nonlymphoid cells and is regarded as a principal trigger for apoptotic cell death of lymphoid cells and hepatocytes (Galle et al., 1995; Nagata, 1997) . In both human and murine liver, Fas and TNF-receptor I (TNF-RI) can independently trigger apoptosis. Indeed, the administration of an activating anti-Fas antibody to mice leads to lethal liver destruction within hours due to extensive apoptosis of hepatocytes (Ogasawara et al., 1993; Leist et al., 1996) . Upon ligand binding and trimerization of Fas, the intracellular death domain of the receptor associates with several proteins forming a death-inducing signaling complex (DISC) through which the recruitment and activation of caspase-8 is initiated (Medema et al., 1997; Schulze-Osthoff et al., 1998) . This event, in turn, triggers a cascade of proteolytic interconversions of procaspases, including downstream caspases such as caspase-3 and -7, which finally execute the proteolytic cleavage of various structural and signal proteins (Zhivotovsky et al., 1997; Hirata et al., 1998; Thronberry and Lazebnik, 1998; Widmann et al., 1998) . The ultimate outcome of this cascade is apoptosis. TNF-a also plays an integral role in the injury and cell death that occurs in hepatocytes following toxin-induced liver damage. TNF-a-induced cell death is mainly transduced through TNF-RI and the signaling pathway is similar to Fas-induced apoptosis (Schulze-Osthoff et al., 1998) .
There have been several reports describing the modulation of Fas-or TNF-RI-mediated apoptosis by GSH. According to these reports, acute GSH depletion induced insensitivity to death receptor stimulation (Hentze et al., 1999 (Hentze et al., , 2000 , while during prolonged GSH depletion increased death receptor-mediated apoptosis was observed (Chiba et al., 1996; Colell et al., 1998; Xu et al., 1998) . The reports strongly indicated that Nrf2 activity may influence the sensitivity of death signaling, but the relationship between Nrf2 and apoptotic signaling was not clearly characterized. Recently, Kotlo et al. (2003) demonstrated that inactivation of Nrf2 by antisense or by using a membranepermeable dominant-negative polypeptide sensitized cells while, conversely, overexpression of Nrf2 protected cells from Fas-induced apoptosis. In addition, they demonstrated that N-acetyl-l-cysteine (NAC), a precursor to GSH, protected cells from Fas-mediated killing in HeLa cells.
In this report, we have analysed the sensitivity of death signaling (Fas-and TNF-a-mediated apoptosis) in Nrf2-deficient mice and demonstrated a high susceptibility to death signals in vivo. Preadministration of glutathione ethyl monoester (GSH-OEt), which upregulates GSH, canceled the observed enhanced sensitivity. This indicates that the low intracellular GSH levels that resulted from Nrf2 deficiency are a primary cause for the susceptibility.
To investigate the role of Nrf2 in Fas-mediated apoptosis, cultured Nrf2-deficient thymocytes were examined in the presence of an agonistic anti-Fas antibody. Our results showed that a deficiency in Nrf2 increased the percentage of apoptotic thymocytes following Fas stimulation ( Figure 1a ). The anti-Fas antibody, at a concentration of 1 mg/ml, induced 60% of cell death in thymocytes from Nrf2-deficient mice while, using the same treatment, 40% of cells from wild-type mice died (Po0.05). Recently, it has been found that prolonged GSH depletion enhances Fasmediated apoptosis (Haouzi et al., 2001) . We and others reported that intracellular GSH levels were reduced in Nrf2-deficient cells (Chan and Kwong, 2000; Ishii et al., 2000) . Therefore, we suspected that the observed sensitivity of cultured thymocytes to Fasmediated apoptosis could be due to a depletion of cellular GSH levels resulting from a deficiency in Nrf2. The administration of GSH-OEt can increase the intracellular GSH concentration in vitro and in vivo (Chen et al., 2001; Rahman et al., 2001) . Therefore, we Figure 1 Effects of Nrf2 deficiency on cultured thymocytes treated with an agonistic anti-Fas antibody. The generation of Nrf2-deficient mice has been previously described (Itoh et al., 1997) . The present study utilized 12-week-old mice from the same litters with an ICR background. Freshly isolated thymocytes from Nrf2-deficient, chronically treated with BSO (6 weeks) and untreated wild-type mice were incubated overnight with the indicated concentrations of the anti-Fas antibody. The cells were washed with DMEM supplemented with 10% heat-inactivated fetal bovine serum, 0.5 mm 2-mercaptoethanol, 2 mm glutamine, 1 mm HEPES (pH 7.4), and antibiotics (all from Invitrogen). The cells were again washed in medium before use in subsequent tissue culture experiments. The cells (1 Â 10 6 /ml) were incubated with various concentrations of the anti-Fas antibody (Jo-2, BD Bioscience) for 12 h. Cell viability was determined by trypan blue exclusion. The cells were preincubated with GSH-OEt (obtained from WAKO) (2 mm for 15-20 min) to increase the intracellular pool of GSH. Each Bar represents the mean7s.d. (a) Survival rate of Nrf2-deficient thymocytes after Fas stimulation was significantly decreased (Po0.05) compared with wild-type thymocytes. Nrf2 deficiency increased the percentage of apoptotic thymocytes after Fas stimulation. *Significant difference from wild-type thymocytes (Po0.05). (b) GSH-OEt protected Nrf2-deficient thymocytes against Fas-mediated apoptosis. Thymocytes were preincubated with 2 mm GSH-OEt. There was no significant difference in the survival rate between Nrf2-deficient and wild-type thymocytes with 2 mm GSH-OEt. (c) The survival of wild-type thymocytes chronically treated with BSO was significantly decreased after Fas stimulation (Po0.05) compared with untreated wild-type thymocytes. BSO, a specific GSH synthesis inhibitory agent, increased the percentage of apoptotic thymocytes after Fas stimulation, similar to Nrf2 deficiency. **Significant difference from BSO-untreated wild-type thymocytes (Po0.05). (d) GSH-OEt protected thymocytes that were chronically treated with BSO against Fas-mediated apoptosis. There was no significant difference in the survival rate between BSO-treated and untreated wild-type thymocytes with 2 mm GSH-OEt. (e) GSH levels of thymocytes were examined pre-and post-anti-Fas antibody administration. GSH levels were measured using a Total Glutathione Quantification Kit (DOJINDO). The GSH levels of Nrf2-deficient thymocytes were significantly reduced compared to wild-type thymocytes, being decreased to almost the same level as that of BSO-treated thymocytes. GSH-OEt addition increased the GSH levels of Nrf2-deficient and BSO-treated thymocytes to almost the same level as that of Nrf2 wild-type thymocytes. (Figure 1b) . These results suggest that the enhanced sensitivity of the Fas signal in Nrf2-deficient thymocytes was due to a decrease in the intracellular GSH levels. However, due to the complicated nature of the GSH system, it is not possible to exclude the possibility that the administered GSH affected the adequate induction of some alternative adaptor molecule(s), whose function could be to prevent Fas-mediated apoptosis. To confirm the hypothesis that the enhanced sensitivity of the Fas signal was due to a decrease in the intracellular GSH levels, we analysed mice chronically treated
Nrf2 and death signals N Morito et al with buthionine sulfoximine (BSO). BSO is a specific GSH synthesis inhibitor that when administered to mice serves as a model of chronic GSH depletion (Srivastava et al., 2000) . Wild-type mice were given water supplemented with BSO (400 mg/kg/day) for 6 weeks. After 6 weeks, thymocytes were isolated from BSO-treated and control (untreated) wild-type mice. Analyses showed that Fas stimulation resulted in a larger percentage of apoptotic cells among BSO-treated thymocytes compared to wild-type controls (Figure 1c) . Furthermore, the addition of GSH-OEt to BSO-treated thymocytes re-established the sensitivity of Fasmediated apoptosis to the level of BSO-untreated mice thymocytes (Figure 1d ). These results support the hypothesis that chronic GSH depletion enhances Fas-mediated apoptosis in vitro.
In the same experiment, we also determined the intracellular levels of GSH of thymocytes (Figure 1e ). The GSH level of Nrf2-deficient thymocytes was decreased to almost the same level as that of BSOtreated wild-type thymocytes. GSH-OEt addition increased the GSH levels of Nrf2-deficient and BSOtreated thymocytes to the same level as that of Nrf2 wild-type thymocytes. These results also support the hypothesis that chronic GSH depletion enhanced Fas-mediated apoptosis in vitro.
It is well known that the administration of anti-Fas antibody to mice can induce fulminant hepatitis as a result of Fas-mediated apoptosis (Ogasawara et al., 1993) . The effect of hepatocellular apoptosis in vivo triggered by the anti-Fas antibody in Nrf2-deficient mice was examined. The anti-Fas antibody (Jo-2, 2 mg/mouse) was administered intraperitoneally to Nrf2-deficient and wild-type mice. Serum alanine aminotransferase (ALT) activities were determined as indices of hepatotoxicity. Serum ALT activity after Fas stimulation was significantly increased in Nrf2-deficient mice compared to Nrf2 wild-type mice (Po0.05) ( Table 1) . At 12 h after anti-Fas antibody administration, ALT activity in sera from Nrf2-deficient mice had increased to over 10 000 IU/l, while that of wild-type mice was around 5000 IU/l. Three out of five Nrf2-deficient mice were already dead at 8 h after injection. To prove that the enhancement of hepatitis in Nrf2-deficient mice was also due to a decrease in intracellular GSH levels, GSH-OEt was administered before anti-Fas antibody injection. The addition of GSH-OEt blocked the enhancement of Fas-induced fulminant hepatitis, suggesting that a Anti-Fas antibody (Jo-2, 2 mg/mouse) was administered intraperitoneally as a mixture in 0.2 ml of pyrogen-free saline to 12-week-old Nrf2-deficient and wild-type (BSO-treated and -untreated) mice. At 0, 4, 8, and 12 h after injection, blood was collected and serum ALT activities were determined as indices of hepatotoxicity using an automated analyser (DRY-CHEM 3500; Fuji Film). GSH-OEt (20 mg/mouse) was injected intravenously 2 h before anti-Fas antibody injection to increase the intracellular GSH level. Results are expressed as mean7s.d. for three to five mice. The survival rate indicates the number of survived/all mice. *Significantly different from wild-type (BSO-untreated) mice (Po0.05) TNF-a (0.5 mg) (obtained from BD Bioscience) was administered intraperitoneally as a mixture in 0.2 ml of pyrogen-free saline to 12-week-old Nrf2-deficient and wild-type (BSO-treated and -untreated) mice. d-Galactosamine hydrochloride (GalN) (obtained from Nacalai Tesque) was preinjected intravenously to increase the susceptibility of mice to hepatotoxicity 30 min before TNF-a injection. GSH-OEt (20 mg/mouse) was injected intravenously 2 h before TNF-a injection to assess the importance of the intracellular GSH level. At 0, 4, 8, and 12 h after injection, blood was collected and serum ALT activities were determined. Results are shown as mean7s.d. for three to five mice. The survival rate indicates number of survived/all mice. *Significantly different from wild-type mice (Po0.05)
Nrf2 and death signals N Morito et al low level of intracellular GSH might be the cause of the enhancement. To confirm this theory, we investigated the effect of chronically treating the mice with BSO. Serum ALT activity after Fas stimulation was significantly increased in BSO-treated wild-type mice compared to untreated wild-type mice (Po0.05) ( Table 1 ). The addition of GSH-OEt cancelled the enhancement of Fas-induced fulminant hepatitis in BSO-treated mice. These results suggest that a low level of intracellular GSH could be the cause of the enhancement in vivo. Figure 2 Nrf2 deficiency enhanced TNF-a-mediated apoptosis and GSH-OEt rescued Nrf2-deficient mice from TNF-a-mediated apoptosis. Mice were killed 12 h after TNF-a (0.5 mg) injection. GalN was preinjected intravenously 30 min before TNF-a injection. GSH-OEt (20 mg) was injected 2 h before TNF-a administration to increase intracellular glutathione levels. The liver was excised, fixed with 10% buffered formalin, sectioned at a thickness of 5 mm, and stained with hematoxylin and eosin for light microscopic examination. (a) Liver section of wild-type mouse: a few apoptotic hepatocytes exhibit apoptotic nuclei. (b) Nrf2-deficient mouse: numerous apoptotic hepatocytes were observed (arrows indicate apoptotic nuclei). (c) Nrf2-deficient mouse with GSH-OEt administration: apoptotic cells were decreased by the addition of GSH-OEt. (d) BSO-treated wild-type mouse: numerous apoptotic hepatocytes were observed as seen in Nrf2-deficient mouse (arrows also indicate apoptotic nuclei). (e) GSH levels of livers were examined pre-and post-TNF-a administration. The total GSH level was measured in homogenized liver samples. The GSH level of Nrf2-deficient livers was significantly reduced compared to wild type being decreased to almost the same level as that of BSO-treated livers. GSH-OEt addition increased the GSH levels of Nrf2-deficient and BSO-treated livers to almost the same level as that of Nrf2 wild-type liver. *Significant difference from untreated wild-type livers (Po0.05)
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Fas and TNF-RI share homology at their cytoplasmic death domain, a region necessary for apoptotic signaling (Schulze-Osthoff et al., 1998) . d-Galactosamine (GalN) is well known to increase the susceptibility of mice to hepatotoxicity and the lethal effects of TNF-a. Therefore, the effect of TNF-a on hepatocellular apoptosis in GalN-sensitized Nrf2-deficient mice was examined. TNF-a (0.5 mg/mice) was administered intraperitoneally to GalN-sensitized Nrf2-deficient and wild-type mice. The result showed that serum ALT activity after TNF-a administration was significantly increased in Nrf2-deficient mice compared to wild-type mice. The mean ALT activity in the sera from Nrf2-deficient mice was 873274413 IU/l at 12 h after induction (Table 2 ). On the other hand, the ALT activity of wild-type mice was less than 2000 IU/l when taken at the same time point. This represents a fourfold difference of ALT activity between these two groups. GSH-OEt addition decreased the ALT activity in Nrf2-deficient mice to almost the same level as that of wild-type mice. To investigate the influence of GSH depletion, we examined wildtype mice chronically treated with BSO. Serum ALT activity after TNF-a stimulation was significantly increased in BSO-treated wild-type mice compared to untreated wild-type mice (Po0.05) ( Table 2 ). The addition of GSH-OEt decreased the enhancement of TNF-a-induced fulminant hepatitis in BSO-treated wildtype mice. This result suggested that a low level of intracellular GSH would be the cause of the enhanced TNF-a-mediated apoptosis.
Histopathological examination revealed that the number of apoptotic hepatocytes was increased in Nrf2-deficient mice compared to wild-type mice (Figure 2) . Massive hepatocyte apoptosis, as judged by the frequent appearance of nuclear fragmentation and a hyperchromatic nuclear membrane, was observed in Nrf2-deficient mice (Figure 2b ). Further major pathological signs included diffuse congestive hemorrhagic foci (Figure 2b ). In contrast, liver specimens from a comparable area taken from mice injected with GSH-OEt before TNF-a administration showed a morphology (Figure 2c ) that was indiscernible from that of wild-type mice (Figure 2a) . BSO-treated wildtype mice revealed massive hepatocyte apoptosis by TNF-a administration as well as Nrf2-deficient mice (Figure 2d ). The administration of GSH-OEt to BSO-treated wild-type mice re-established the sensitivity of TNF-a-mediated apoptosis to the level of wild-type mice as judged by histological appearance (data not shown). The histological analyses also support the fact that Nrf2 deficiency enhances the sensitivity of TNF-amediated apoptosis as a consequence of GSH depletion.
To confirm the effect of GSH on TNF-a-mediated apoptosis in vivo, we determined the total liver GSH levels (Figure 2e ). Mice were killed 4 h after TNF-a and GalN administration. Livers were homogenized and the total GSH levels were measured. The GSH level of Nrf2-deficient livers was decreased to almost the same level as that of BSO-treated wild-type livers. GSH-OEt addition increased the GSH levels of Nrf2-deficient and BSOtreated wild-type livers to almost the same level as that of Nrf2 wild-type livers. These results suggest that chronic GSH depletion can enhance TNF-a-mediated apoptosis in vivo.
An accumulating number of reports describe the relationship between Nrf2 and various kinds of stresses. Cho et al. (2002) reported that Nrf2 had a key protective role during hyperoxic lung injury. Enomoto et al. (2001) and Chan et al. (2001) clearly demonstrated an enhanced susceptibility to acetaminophen in Nrf2-deficient mice. We also reported that Nrf2 female mice developed autoimmune glomerulonephritis probably due to susceptibility to oxidative stress (Yoh et al., 2001) . In addition, Ramos-Gomez et al. (2001) showed that Nrf2 was central to the constitutive and inducible expression of phase two enzymes in vivo and dramatically influences susceptibility to carcinogens. However, few studies reported the relationship between Nrf2 and apoptosis. This study is the first report describing Nrf2 as regulating the sensitivity of death receptor signals through intracellular glutathione levels in vivo. The inhibition of the death signal is a novel role of Nrf2. Possibly, the observed enhancement in death signals caused by a deficiency in Nrf2 is a safety mechanism to eliminate cells that have accumulated damage as a consequence of an inadequate stress response. Further analyses must be performed to explore the relationship between apoptotic regulation by Nrf2 and various stresses including diseases.
